Juno Therapeutics (JUNO) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Juno Therapeutics (JUNO) Deal Keeps It at the Cutting Edge of CAR Technology, Leerink Partners Says
May 12, 2015 7:57 AM EDTLeerink Partners Howard Liang reiterated an Outperform rating and $74 price target on Juno Therapeutics (NASDAQ: JUNO) following Q1 earnings and a deal to acquire Stage Cell Therapeutics GmbH. The deal, according to the analyst, keeps JUNO on the cutting edge of CAR Technology.
commented, "Along... More
Juno Therapeutics (JUNO) to Acquire German-Based Stage Cell Therapeutics for ~$59M
May 11, 2015 4:08 PM EDTJuno Therapeutics (NASDAQ: JUNO) acquired Stage Cell Therapeutics GmbH, a privately held biotechnology company based in Munich and Göttingen, Germany. The transaction furthers Juno's strategy of being a world leader in process development and the manufacturing of cellular therapies. The acquisition provides Juno access to transformative cell selection and activation capabilities, next generation manufacturing automation technologies, enhanced control of its supply chain, and lower expected long-term cost of goods. Juno plans to operate the acquired company,... More
